Question: CO3. Oil Dusters (Mild) C04 Col Clusters (offield) CD4SRC (ned) D 1. First, Describe An Immunohistochemistry Assay (IHC) And Why It’s Used To Diagnose Cancer. Above You Have Eight Patients With Prostate Cancer. IHC Was Done To Visualize The Expression Of The Prostate Specific Antigen (PSA) Which Patient/patients Do You See Expression Of PSA When Looking …

CO3. oil dusters (Mild) C04 col clusters (offield) CD4SRC (ned) D 1. First, describe an immunohistochemistry assay (IHC) and why it’s used to diagnose cancer. Above you have eight patients with prostate cancer. IHC was done to visualize the expression of the prostate specific antigen (PSA) Which patient/patients do you see expression of PSA when looking at the IHC’s (Panels A-I). Which do not express PSA? Which patients have aggressive prostate cancer? 2. Above you have four patients with HER2 positive breast cancer. Breast tissue was removed and IHC was done on the tissue samples to test for HER2 expression. The lab wanted to know how much HER2 expression was in each tissue sample. Which samples show HER2 expression and which samples do not? Which patient/patients would you treat with Lapatinib, chemotherapy or radiation? What would be the IHC score for each patient? ErbB2 3.1 3.1 Lrig Lrig C24 C24 Receptor GAPDH 3. What type of assay or experiment is being done in the figure? Above are Oro 2. Above you have four patients with HER2 positive breast cancer. Breast tissue was removed and IHC was done on the tissue samples to test for HER2 expression. The lab wanted to know how much HER2 expression was in each tissue sample. Which samples show HER2 expression and which samples do not? Which patient/patients would you treat with Lapatinib, chemotherapy or radiation? What would be the IHC score for each patient? ErbB2 3.1 3.1 Lrig Lrig C24 C24 Receptor GAPDH 3. What type of assay or experiment is being done in the figure? Above are individuals with ErbB2 positive breast cancer. Lrig and C24 are both tumor suppressor proteins. The positive control is labeled 3.1, which shows increased ErbB2 expression without the co-transfection with the tumor suppressor proteins. Each treatment was done in duplicates. Which of the tumor suppressors is most beneficial in treating ErbB2 positive breast cancer? What is happening to the ErbB2 receptor in the presence of the tumor suppressors, Lrig1 and C24? What is GAPDH and why is it used in this assay? How is cancer affected by the increase or decrease in ErB2 expression?